Clicky

Lava Therapeutics B.V.(LVTX)

Description: Lava Therapeutics B.V., a biotechnology company, develops proprietary Vγ9Vδ2 T-cell engagers. It develops immune oncology biopharmaceuticals that delivers treatment in combination with immune recruiting and activating functionality. The company was founded in 2016 and is based in Utrecht, the Netherlands.


Keywords: Biotechnology Biopharmaceutical Life Sciences Pharmacy Health Sciences Immunocore

Home Page: www.lavatherapeutics.com

LVTX Technical Analysis

Yalelaan 60
Utrecht, 3584 CM
Netherlands
Phone: 31 630 00 30 35


Officers

Name Title
Mr. Stephen Allen Hurly M.B.A., M.Sc. CEO, Pres & Exec. Director
Mr. Peter Ros VP of Fin.
Mr. Fred M. Powell CPA Chief Financial Officer
Dr. Hans van der Vliet M.D., Ph.D. Chief Scientific Officer
Ms. Amy Garabedian J.D. Gen. Counsel & Corp. Sec.
Mr. Wouter van Hunnik VP & Head of HR
Dr. Benjamin Winograd M.D., Ph.D. Chief Medical Officer
Dr. Ton Adang Ph.D. Chief Devel. Officer
Dr. Paul W. H. I. Parren Ph.D. Exec. VP, Head of R&D and MD

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0.4157
Price-to-Book MRQ: 1.8811
Price-to-Sales TTM: 5.8096
IPO Date: 2021-03-25
Fiscal Year End: December
Full Time Employees: 55
Back to stocks